Topical Resiquimod 0.01% Gel Decreases Herpes Simplex Virus Type 2 Genital Shedding: A Randomized, Controlled Trial | Zendy

Karen E. Mark | Zendy; Lawrence Corey | Zendy; TzeChiang Meng | Zendy; Amalia Magaret | Zendy; MeeiLi Huang | Zendy; Stacy Selke | Zendy; Herbert B. Slade | Zendy; Stephen K. Tyring | Zendy; Terri Warren | Zendy; Stephen L. Sacks | Zendy; Peter A. Leone | Zendy; Vicki A. Bergland | Zendy; Anna Wald | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Topical Resiquimod 0.01% Gel Decreases Herpes Simplex Virus Type 2 Genital Shedding: A Randomized, Controlled Trial

Author(s) -

Karen E. Mark,

Lawrence Corey,

TzeChiang Meng,

Amalia Magaret,

MeeiLi Huang,

Stacy Selke,

Herbert B. Slade,

Stephen K. Tyring,

Terri Warren,

Stephen L. Sacks,

Peter A. Leone,

Vicki A. Bergland,

Anna Wald

Publication year - 2007

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/513276

Subject(s) - herpes simplex virus , viral shedding , immune system , medicine , immunology , lesion , virus , gastroenterology , biology , virology , pathology

Resiquimod, an investigational immune response modifier and Toll-like receptor (TLR) 7 and 8 agonist, stimulates production of cytokines that promote an antigen-specific T helper type 1 (Th1)--acquired immune response. In animal models, induction of Th1-specific responses modifies experimental herpes simplex virus (HSV) infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research